Erythropoietin therapy in predialysis patients | Zendy

Nada Dimković | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Erythropoietin therapy in predialysis patients

Author(s) -

Nada Dimković

Publication year - 2003

Publication title -

medicinski pregled

Language(s) - English

Resource type - Journals

eISSN - 1820-7383

pISSN - 0025-8105

DOI - 10.2298/mpns0312529d

Subject(s) - medicine , erythropoietin , anemia , dialysis , renal replacement therapy , nephrology , uremia , intensive care medicine , heart failure , kidney disease , coronary artery disease , end stage renal disease , renal function , disease , cardiology

Anemia is recognized as a very important non-traditional risk factor for cardiovascular morbidity and mortality in patients with uremia. Despite many advantages of erythropoietin therapy, the number of patients treated with this drug is modest, particularly during the pre-end stage renal disease. Patients with chronic renal failure are at risk to develop coronary artery disease, left ventricular hypertrophy and chronic heart failure when hemoglobin concentration falls below 10 g/dl and creatinine clearance under 60 ml/min.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research